TESARO Announces Submission of Investigational New Drug Application for Anti-TIM-3 Antibody TSR-022 to the U.S. FDA
April 25, 2016 08:05 ET
|
TESARO, Inc.
WALTHAM, Mass., April 25, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the submission of an Investigational New Drug (IND)...